3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
11
Prostatic Neoplasms
8
Neoplasm Metastasis
6
Ovarian Neoplasms
4
Neoplasms
4
Triple Negative Breast Neoplasms
3
Endometrial Neoplasms
3
Small Cell Lung Carcinoma
2
Fallopian Tube Neoplasms
2
mCRPC
1
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Pheochromocytoma
1
Pathologic Complete Response
1
Paraganglioma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Interventions
pembrolizumab
12
Pemetrexed
9
Cisplatin
9
Nivolumab
8
Carboplatin
8
Ipilimumab
7
Cyclophosphamide
6
fludarabine
5
durvalumab
4
tremelimumab
2
Radiotherapy, Intensity-Modulated
2
Gemcitabine
2
Cerebral Decortication
2
tocilizumab
1
tislelizumab
1
tazemetostat
1
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
bintrafusp alfa protein, human
1
avelumab
1
atezolizumab
1
Tumor Burden
1
Temozolomide
1
Tablets
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma
×
talazoparib
×
1 year
×
Clear all
No trials found.